Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

NUV-868

Small molecule · Inhibitor of BRD4 · developed by Nuvation Bio

Phase 1 Most advanced trial (none active)
NUVB Developer
1 Registered trials

What is NUV-868?

NUV-868 is an orally bioavailable inhibitor that is selective for the BD2 domain of the BRD4 BET protein. By blocking the interaction between BET proteins and acetylated histones, it disrupts chromatin remodeling and suppresses oncogene expression. It is being studied in solid tumors including ovarian, pancreatic and prostate cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
BRD4
Mechanism
Inhibitor of BRD4
Pathways
BET protein binding to acetylated histones, chromatin remodeling, oncogene expression suppression
Therapy area
Oncology
Developer
Nuvation Bio Inc. (NUVB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05252390 Phase 1 Advanced Solid Tumor Terminated NUVB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorCancer of OvaryCancer of PancreasCancer of ProstateCancer of the OvaryCancer of the PancreasCancer of the ProstateOvarian CancerOvary CancerOvary NeoplasmPancreas CancerPancreas NeoplasmPancreatic CancerProstate Cancer

Other drugs acting on BRD4

AZD5153 Phase 2/3

More from Nuvation Bio

Taletrectinib FDA approved Inixaciclib Phase 1/2 NUV-1511 Phase 1/2 Safusidenib Phase 3 Safusidenib Erbumine Early Phase 1

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the NUVB page.

Follow NUVB, the company behind NUV-868

See NUVB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NUVB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.